Telix and RefleXion expand partnership for prostate cancer treatment

Press releases may be edited for formatting or style | June 10, 2022 Molecular Imaging Rad Oncology

Telix's lead product, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection), also known as 68Ga PSMA-11 injection, has been approved by the U.S. Food and Drug Administration (FDA),[7] and by the Australian Therapeutic Goods Administration (TGA).[8] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[9] and Canada.[10] Illuccix is currently being investigated in combination with BgRT treatment.

SOURCE Telix Pharmaceuticals Limited

Back to HCB News

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money



You Must Be Logged In To Post A Comment Sign In If you've already created an account, use your email address and password to sign in using the form below. Login Problems: Click here if you are having login issues. Email address: Password: Forgot your password? Login Problems? View our Legal Notice and Privacy Notice Register Registration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now!